Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changchun Deng

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphomaSalvia Jain, Xavier Jirau-Serrano, Kelly M Zullo, et al.
Blood|October 28, 2016
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesChangchun Deng, Mark R Lipstein, Luigi Scotto, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Blood|November 10, 2020
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 studyLorenzo Falchi, Helen Ma, Sandra Klein, et al.
Blood|September 1, 2019
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 studyOwen A O'Connor, Lorenzo Falchi, Jennifer K Lue, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphomaSalvia Jain, Xavier Jirau-Serrano, Kelly M Zullo, et al.
Blood|October 28, 2016
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesChangchun Deng, Mark R Lipstein, Luigi Scotto, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Blood|November 10, 2020
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 studyLorenzo Falchi, Helen Ma, Sandra Klein, et al.
Blood|September 1, 2019
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 studyOwen A O'Connor, Lorenzo Falchi, Jennifer K Lue, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Pageof 4